Humanized Anti-α4β7 Antibody Dosing for GvHD Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Graft-versus-host disease (GvHD) remains a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with current prophylaxis strategies failing to completely prevent the development of GvHD, particularly in the gastrointestinal tract.
Innovation Solution
Administering an antagonist of human α4β7 integrin, such as a humanized anti-α4β7 antibody (e.g., vedolizumab), to patients undergoing allo-HSCT, following a specific dosing regimen that includes initial, subsequent, and third doses at predetermined intervals, to block the trafficking of T cells to secondary lymphoid organs and prevent the evolution of acute GvHD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current prophylaxis strategies are used, then some protection against GvHD is achieved, but GvHD still develops in 30% to 50% of allo-HSCT recipients
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of GvHD by blocking the α4β7 integrin pathway, which mediates T-cell trafficking to gut-associated lymphoid tissues. This selective extraction of the harmful pathway allows prevention of GvHD without broadly suppressing the immune system, thereby addressing the limitation of current prophylaxis strategies that fail to prevent GvHD in 30-50% of recipients.
Solution Approach 2:
The invention applies local quality by specifically targeting the gut-homing pathway through α4β7 integrin blockade, rather than applying systemic immunosuppression. This localized approach prevents GvHD in the gastrointestinal tract while preserving systemic immune function, thereby improving prophylaxis effectiveness and reducing the incidence of GvHD compared to conventional strategies.
2Object-affected harmful factors
If T-cell depletion strategies are used, then GvHD is reduced, but systemic immunosuppression increases
Solution Approach 1:
The patent employs local quality by specifically blocking the α4β7 integrin-mediated trafficking pathway to gut-associated lymphoid tissues, rather than depleting T-cells systemically. This localized intervention reduces GvHD severity by preventing pathogenic T-cell homing to the gut while preserving overall immune function, thereby resolving the contradiction between GvHD reduction and immune suppression.
Solution Approach 2:
The invention uses an anti-α4β7 integrin antibody as an intermediary molecule that selectively blocks the interaction between T-cells and gut-associated lymphoid tissues. This intermediary approach allows reduction of GvHD severity by intercepting the specific trafficking pathway without causing broad T-cell depletion or systemic immunosuppression.
3Object-affected harmful factors
If gut decontamination is used, then GvHD is reduced, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent extracts and targets the critical gut-homing pathway by blocking α4β7 integrin, thereby reducing GvHD risk through a single molecular target rather than requiring complex multi-step gut decontamination protocols. This extraction of the key pathological mechanism simplifies the treatment approach while maintaining effectiveness in preventing GvHD.
Solution Approach 2:
The invention changes the therapeutic parameter from complex procedural interventions (gut decontamination) to a targeted molecular blockade of α4β7 integrin. This parameter change reduces treatment regimen complexity by replacing multiple procedural steps with a single mechanism-based intervention that specifically reduces GvHD risk.
Data Source
AI summary
A method for treating or preventing GvHD in a human patient, comprising administering to a patient suffering from GvHD or at risk for GvHD, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has or is going to have an allogeneic stem cell transplantation, and wherein the dosing regimen prevents, improves or eliminates GvHD.